Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07261085 · ClinicalTrials.gov registry record
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
A clinical trial of COVID-19, sponsored by Pfizer.
- Active
- Registry status
- 99,000
- Enrollment target
- 1
- Study location
NCT07261085: Active study of COVID-19, sponsored by Pfizer.
NCT07261085 is a study of COVID-19 that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 99,000 participants, above the 38,133-participant average among 298 other COVID-19 trials with a reported enrollment target (160% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07261085, a study of COVID-19, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 99,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about the effects of the study medicine called Paxlovid \[nirmatrelvir-ritonavir/PF-07321332\], for the potential treatment of COVID-19. This study will use patient health records in Ontario, to find people who were sick with COVID-19 and visited a pharmacist to be treated, anytime from December 1st, 2022, to March 31st, 2024. To be included in our study, the people must be over 18 years of age and be registered in the Ontario health system for at least one year. People were not included in our study if they have been pregnant in the past year or have serious kidney or liver disease. We will separate the people in the study into two groups: those who received treatment with Paxlovid \[nirmatrelvir-ritonavir/PF-07321332\] and those who received no treatment. We will monitor their healthcare visits or if they die for any reason, for up to 60 days after the date that they visited their pharmacist. Then we will compare participant experiences when they are taking the study medicine to when they are not. This will help us determine if the study medicine is effective.
Conditions Studied
Interventions
- OTHER No treatment
- DRUG nirmatrelvir-ritonavir
Study Locations (1)
New York
- Pfizer New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,000 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2026-03-30 |
What the registry record for NCT07261085 still lists
NCT07261085 is an observational study that tracks outcomes without assigning an intervention. Its 99,000 participants enrollment target places it among the larger protocols in the corpus, above the 38,133-participant average among 298 other COVID-19 trials with a reported enrollment target (160% higher).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which No treatment is the first listed.
NCT07261085 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07261085 about?
NCT07261085 is a clinical study titled "A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.". The purpose of this study is to learn about the effects of the study medicine called Paxlovid \[nirmatrelvir-ritonavir/PF-07321332\], for the potential treatment of COVID-19. This study will use patient health records in Ontario, to find people who were sick with COVID-19 and visited a pharmacist t...
What is the current status of trial NCT07261085?
This trial is currently active not recruiting. The enrollment target is 99,000 participants. The study started on 2025-10-27. Estimated completion is 2026-03-30.
What conditions does trial NCT07261085 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07261085?
The interventions under investigation include: No treatment (OTHER), nirmatrelvir-ritonavir (DRUG).
Who is sponsoring clinical trial NCT07261085?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07261085 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07261085's enrollment target sits among peer trials
99,000 4th of 298 higher than 295 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01351545 · 99,999 participants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NCT02620852 · 100,000 participants · NA
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- NCT03277365 · 100,000 participants · NA
MyGeneRank: A Digital Platform for Next-Generation Genetic Studies
- NCT04281823 · 100,000 participants
DeBakey Cardiovascular Magnetic Resonance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI